摘要
目的:探讨米非司酮治疗子宫内膜异位症的临床疗效及其安全性。方法:选取子宫内膜异位症的患者60例,于月经来潮后5天内给予米非司酮10mg/d口服,共3个月,比较用药前后症状、体征改善情况,生殖激素的变化,不良反应的发生及停药后的妊娠情况等。结果:用药3个月后患者痛经等症状有所改善,有效率达96.67%;用药后后陷凹结节缩小,子宫活动度改善,卵巢囊肿缩小,差异有统计学意义(P<0.05);用药期间闭经40例(66.67%),18例(30.00%)月经减少;用药前与月经恢复后血清雌二醇(E2)、孕激素(P)、卵泡刺激素(FSH)及黄体生成素(LH)水平无明显变化(P>0.05),9例(15.00%)出现转氨酶轻微升高,15例(25.00%)出现阴道不规则点滴出血;停药后1～7个月妊娠6例(10.00%)。结论:米非司酮治疗子宫内膜异位症,症状改善明显,对下丘脑-垂体-卵巢性腺轴无明显影响,不良反应少,对提高妊娠率有一定帮助。
Objective： To explore the clinical effects and safety of mifepristone on the treatment of endometriosis. Methods ： 60 cases with endometriosis were included in this study, and oral mifepristone （lOmg/d） was administrated within 5 days after menstrual onset for 3 months. Symptoms pre - and post - medication, improvement of physical sign, variation of gonadal hormones, occurrence of adverse effects and pregnancy situation after drug withdrawal were observed and compared. Results： The dysmenorrhea was relieved after 3 months of medication, with the effective rate 96.67%. The size of vaginal foruix nodus and ovarian cyst were diminished, and the mobility of uterus was improved after medication, with statistically significant differences （ P 〈 0.05 ）. There were 40 cases with amenorrhea and 18 cases with spanomenorrhea during medication. The levels of serum estradiol （E2 ）, progestogen （P）, follicle stimulating hormone （FSH） and luteinizing hormone （LH） were compared before medication and after menstruation return, and there were no statistical differences （P 〉0.05）. 9 cases （ 15.00% ） with slight elevation of aminopherase, and 15 cases （25.00%） with irregular vagina bleeding were detected. And 6 patients （ 10.00% ） got pregnancy within 1 - 7 months after drug withdrawal. Conclusion： Mifepristone has valuable effects on the treatment of endometriosis, which can markedly improve the clinical symptoms and elevate the pregnancy rate： with little adverse effects and no obvious influence on hypothalamic- pituitary- ovarian （H- P- O） axis.
出处
《中国计划生育学杂志》
北大核心
2009年第1期36-38,共3页
Chinese Journal of Family Planning
